LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
What is Zionism? The different meanings of a contested term 
Gold Prices Slip as Strong Dollar and Hawkish Fed Pressure Bullion 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
Banking scandal rocks Brazil’s politics and the country’s presidential election in October 
China’s robots can run faster than Usain Bolt – now they are being prepared for war 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Petrobras Joins Brazil Diesel Subsidy Program 
Supertanker Orders Surge as US-Iran War Reshapes Oil Trade 
FxWirePro- Crypto Weekly Alpha: ETF Rebounds, L2 Rallies & Key Resistance Levels 
Add as a preferred source on Google
European medical technology companies remain largely insulated from Middle East geopolitical tensions and rising energy costs, according to a recent RBC Capital Markets analysis. The investment bank found that sales exposure to the Middle East ranges between 1% and 3% across the sector, while both energy and freight costs each represent a similarly modest 1% to 3% of sales and cost of goods sold, respectively.
RBC analysts Jack Reynolds-Clark, Natalia Webster, and Charles Weston assessed major players including Alcon, Carl Zeiss Meditec, Coloplast, ConvaTec, Demant, GN Store Nord, Philips, Siemens Healthineers, Smith & Nephew, Sonova, and Amplifon. Although oil is a component in many raw materials used by these companies, the bank emphasized that extensive processing layers significantly dilute oil price volatility's impact on production costs.
Hedging strategies are also helping cushion potential risks. Coloplast has hedged most of its roughly 2% energy-to-COGS exposure through 2025/26, while GN Store Nord has substantially hedged its freight costs, estimated in the low single digits as a percentage of sales. ConvaTec's energy exposure sits between 2% and 3% of cost of goods sold.
Among the companies reviewed, Carl Zeiss Meditec carries the highest regional revenue exposure at 2% to 3% of sales, alongside energy costs near 3% of COGS. Siemens Healthineers disclosed Middle East revenues below 5% of sales and flagged a potential annualized adjusted EBIT impact of 2 to 4 percentage points from supply chain cost pressures before mitigations. Smith & Nephew reported approximately 1.5% exposure across all three risk categories, while Sonova's Middle East sales exposure exceeds 1%, including Israel.
RBC maintained Outperform ratings on Alcon, ConvaTec, and Siemens Healthineers, and expressed a preference for Sonova over a 12-month horizon. The bank remains cautious on Smith & Nephew, Philips, Coloplast, Carl Zeiss Meditec, Demant, GN, and Amplifon. Additionally, RBC flagged helium supply constraints as a concern for imaging-focused companies, though ongoing consumption responsibilities typically transfer to customers after initial MRI delivery.
